References
- Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L. et al. (1999). International autoimmune hepatitis group report: Review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol., 31, 929–938.
- Bolia, R., Goel, A., Srivastava, A. (2021). Systematic review and meta-analysis of thiopurine metabolite levels and biochemical remission in autoimmune hepatitis. Ther. Drug Monit., 43 (5), 609–616. DOI: 10.1097/FTD.0000000000000848.
- Candels, L. S., Rahim, M. N., Shah, S., Heneghan, M. A. (2021). Towards personalised medicine in autoimmune hepatitis: Measurement of thiopurine metabolites results in higher biochemical response rates. J. Hepatol., 75 (2), 324–332. DOI: 10.1016/j.jhep.2021.03.023.
- Czaja, A. J., Carpenter, H. A., Santrach, P. J., Moore, S. B., Taswell, H. F., Homburger, H. A. (1993). Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J. Hepatol., 18, 342–352.
- Díaz-González, Á., Hernández-Guerra, M., Pérez-Medrano, I., Sapena, V., Riveiro-Barciela, M., Barreira-Díaz, A., Gómez, E., Morillas, R. M,, Del Barrio, M., Escudé, L., et al. (2023). ColHai Registry. Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration. Hepatology, 77 (4), 1095–1105. DOI: 10.1097/HEP.0000000000000018.
- Efe, C., Ozaslan, E., Kav, T., Purnak, T., Shorbagi, A., Ozkayar, O., Berlot, A. H., Sökmensuer, C., Muratori, P. (2012). Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmun Rev., 11 (5), 330–334. DOI: 10.1016/j.autrev.2011.09.006.
- European Association for the Study of the Liver (2015). EASL Clinical Practice Guidelines: Autoimmune hepatitis. J. Hepatol., 63, 971–1004. DOI:10.1016/j.jhep.2015.06.030 pmid:26341719
- Feld, J. J., Dinh, H., Arenovich, T., Marcus, V. A, Wanless, I. R., Heathcote, E. J. (2005). Autoimmune hepatitis: Effect of symptoms and cirrhosis on natural history and outcome. Hepatology, 42, 53–62.
- Gatselis, N. K., Zachou, K., Koukoulis, G. K., Dalekos, G. N. (2015). Auto-immune hepatitis, one disease with many faces: Etiopathogenetic, clinico–laboratory and histological characteristics. World J. Gastroenterol., 21, 60–83.
- Gregorio, G. V., Portmann, B., Reid, F., Donaldson, P. T., Doherty, D. G., McCartney, M., et al. (1997). Autoimmune hepatitis in childhood: A 20–year experience. Hepatology, 25, 541–547.
- Hennes, E. M., Zeniya, M., Czaja, A. J. et al. (2008). International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology, 48,169–176. DOI: 10.1002/hep.22322.
- Kogan, J., Safadi, R, Ashur, Y., Shouval, D., Ilan, Y. (2002). Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: A study of 68 patients. J. Clin. Gastroenterol., 35, 75–81.
- Lohse, A. W., Sebode, M., J¸rgensen, M. H., Ytting, H., Karlsen, T. H,, Kelly, D., Manns, M. P., Vesterhus, M. (2020). European Reference Network on Hepatological Diseases (ERN RARE-LIVER); International Autoimmune Hepatitis Group (IAIHG). Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. J. Hepatol., 73 (6), 1496–1506. DOI: 10.1016/j.jhep.2020.07.023.
- Lv, T., Li, M., Zeng, N., et al. (2019). Systematic review and meta-analysis of the incidence and prevalence of autoimmune hepatitis in the Asian, European, and American population. J. Gastroenterol. Hepatol., 34, 1676–1684. DOI: 10.1111/jgh.14746.
- Manns, M. P., Czaja, A. J., Gorham, J. D., Krawitt, E. L., Mieli-Vergani, G., Vergani, D., Vierling, J. M. (2010). American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology, 51 (6), 2193–2213. DOI: 10.1002/hep.23584.
- Moulton, V. R. (2018). Sex hormones in acquired immunity and autoimmune disease. Front. Immunol., 9, 2279. DOI: 10.3389/fimmu.2018.02279.
- Nagamine, K., Peterson, P., Scott, H. S., Kudoh, J., Minoshima, S., Heino, M, et al. (1997). Positional cloning of the APECED gene. Nat. Genet., 17, 393–398.
- Rahim, M. N., Miquel, R., Heneghan, M. A. (2020). Approach to the patient with acute severe autoimmune hepatitis. JHEP Rep., 2, 100149. DOI: 10.1016/j.jhepr.2020.100149.
- Steinmann, S., Lohse, A. W. (2023). Treatment of autoimmune hepatitis: Budesonide does not solve our problems. Hepatology, 77 (4), 1071–1073. DOI: 10.1097/HEP.0000000000000183.
- Terziroli Beretta-Piccoli, B., Mieli-Vergani, G., Vergani, D. (2017). Auto-immune hepatitis: Standard treatment and systematic review of alternative treatments. 23 (33), 6030–6048. DOI: 10.3748/wjg.v23.i33.6030.
- Trivedi, P. J., Hirschfield, G.M. (2021). Recent advances in clinical practice: Epidemiology of autoimmune liver diseases. Gut, 70, 1989–2003. DOI: 10.1136/gutjnl-2020-322362.
- Volk, M. L., Reau, N. (2021). Diagnosis and management of autoimmune hepatitis in adults and children: A patient-friendly summary of the 2019 AASLD guidelines. Clin. Liver Dis. (Hoboken), 17 (2, 85–89. DOI: 10.1002/cld.1080.
- Weiler-Normann, C., Lohse, A. W. (2014). Acute autoimmune hepatitis: Many open questions. J. Hepatol., 61, 727–729. DOI: 10.1016/j.jhep.2014.06.030.
- Werner, M., Wallerstedt, S., Lindgren, S., Almer, S., Björnsson E., Bergquist, A., Prytz, H., Sandberg-Gertzén, H, Hultcrantz, R, Sangfelt, P. (2010). Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scand. J. Gastroenterol., 45, 457–467.
- WHO (2024). Menopause. https://www.who.int/news-room/fact-sheets/detail/menopause (accessed 11.07.2024).